We have successfully carried out a 7-month, longitudinal, multi-modal imaging study of the PTEN deletion in an HCC mouse model and have obtained quantitative PET, MR, and CT imaging biomarkers as a function of disease progression. This evidence concerns the gene PTEN and hepatocellular carcinoma.